<DOC>
	<DOCNO>NCT00378482</DOCNO>
	<brief_summary>This study intend provide access CP-675,206 patient previously receive CP-675,206 clinical trial .</brief_summary>
	<brief_title>A Rollover Study Patients Who Received CP-675,206 Other Protocols , Allow Patients Access CP-675,206 Until This Agent Becomes Commercially Available Development Discontinued .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The subject must already receive CP675,206 another protocol Females childbearing potential must agree practice form effective contraception 12 month follow dose study drug . The definition effective contraception base judgement investigator . Subject must willing able provide write informed consent comply schedule visit trial procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Melanoma tumor</keyword>
</DOC>